儿童非感染性葡萄膜炎中较早使用全身免疫抑制与较少的眼科手术相关
该回顾性研究纳入1998至2013年评估的48例非感染性葡萄膜炎患儿,按诊断时间分为2008年12月前组和2009年1月后组,比较全身免疫抑制启动时机与3.5年内需眼科手术的比例。结果显示第1组69.5%需至少1次眼科手术,第2组26.9%(p=0.005),较早启动甲氨蝶呤和生物制剂与手术需求降低相关。
要点
- 第1组3.5年内需至少1次眼科手术比例为69.5%,第2组为26.9%(p=0.005)。
- 葡萄膜炎发病6个月内启动甲氨蝶呤与3.5年内需眼科手术的似然比降低相关(OR=6.2,95%CI 1.2至33.4;p=0.033)。
- 发病18个月内加用生物制剂与需眼科手术的似然比降低相关(OR 12.57,95%CI 1.28至123.48;p=0.030)。
核心结论
- 较早通过加用免疫抑制治疗控制葡萄膜炎减少了眼科手术的需求。
研究设计与样本
- 回顾性综述,纳入1998至2013年评估的48例非感染性葡萄膜炎患儿。
- 患者分为葡萄膜炎诊断于2008年12月前(第1组)和2009年1月后(第2组)。
- 回顾从葡萄膜炎发病到启动甲氨蝶呤(U-MTX)和加用生物制剂(U-Biologic)的时长。
- 记录3.5年内局部糖皮质激素使用超过每日3次的随访和活动性葡萄膜炎(≥1+细胞)情况。
- 主要结局指标为3.5年内需至少1次眼科手术。
主要发现
- 第1组69.5%的患者在3.5年内需至少1次眼科手术,第2组为26.9%(p=0.005)。
- U-MTX在第1组为28.9±11.8周,第2组为14.2±10.0周(p=0.028)。
- U-Biologic在第1组为134.6±46.0周,第2组为82.3±43.3周(p=0.0016)。
- 局部糖皮质激素使用超过每日3次的时间在第1组为85.9±52.7周,第2组为14.6±11.1周。
- 多因素回归显示葡萄膜炎发病6个月内启动甲氨蝶呤降低3.5年内需眼科手术的似然比(OR=6.2,95%CI 1.2至33.4;p=0.033)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: There is a paucity of large trials investigating the effect of management strategies for paediatric non-infectious uveitis on complications requiring surgery. The purpose of our study is to investigate whether earlier initiation of systemic immunosuppression in paediatric non-infectious uveitis is associated with fewer ophthalmic surgeries. METHODS: A retrospective review was conducted on 48 children with non-infectious uveitis assessed in 1998-2013. Patients were divided into uveitis diagnosed before December 2008 (group 1) and after January 2009 (group 2). Duration from uveitis onset to methotrexate initiation (U-MTX) and biological addition (U-Biologic) were reviewed. Follow-up visits with topical corticosteroids >3 times daily and active uveitis (≥1+ cells) during 3.5 years were documented. The main outcome measure was the need for ≥1 ophthalmic surgery at 3.5 years. RESULTS: In group 1, 69.5% of patients required ≥1 ophthalmic surgery at 3.5 years versus 26.9% in group 2 (p=0.005). U-MTX was 28.9±11.8 weeks and 14.2±10.0 weeks for groups 1 and 2 (p=0.028). U-Biologic was 134.6±46.0 weeks and 82.3±43.3 weeks for groups 1 and 2 (p=0.0016). Corticosteroid use >3 times daily was 85.9±52.7 weeks and 14.6±11.1 weeks for groups 1 and 2. Multivariate regression showed methotrexate initiation within 6 months of uveitis onset lowered the likelihood of needing ophthalmic surgery at 3.5 years (OR=6.2, 95% CI 1.2 to 33.4; p=0.033). Univariate regression demonstrated biological addition within 18 months of uveitis onset reduced the likelihood of requiring ophthalmic surgery (OR 12.57, 95% CI 1.28 to 123.48; p=0.030). CONCLUSION: Earlier control of uveitis by addition of immunosuppressive therapy reduced the need for ophthalmic surgery.
引用
- Cheung CSY, Mireskandari K, Ali A, et al. Earlier use of systemic immunosuppression is associated with fewer ophthalmic surgeries in paediatric non-infectious uveitis. Br J Ophthalmol. 2019. PMID: 31604701. doi:10.1136/bjophthalmol-2019-314875
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。